Free Trial
→ Elon just declared war on your phone (From Stansberry Research) (Ad)tc pixel
NASDAQ:LIVN

LivaNova Q3 2026 Earnings Date & Estimates

LivaNova logo
$76.39 +0.48 (+0.63%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$76.39 0.00 (0.00%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LivaNova is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from LivaNova in Q3 2026

LivaNova is expected to post earnings of $1.06 per share on revenue of $381.07 million. LivaNova last reported on August 6, 2026, posting $1.26 per share and beating the $1.09 consensus estimate. LivaNova has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$1.06
Expected Revenue
$381.07 million

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$1.26 (Beat by +$0.17)
Last Quarter Revenue
$390.59 million
EPS Beat Rate
8 of last 8 quarters

Prepare for the Q3 2026 Call

LivaNova Q3 2026 Earnings FAQ

LivaNova (NASDAQ:LIVN) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens.

LivaNova's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect LivaNova to post earnings of $1.06 per share for Q3 2026.

The consensus revenue estimate for LivaNova is $381.07 million for Q3 2026.

LivaNova Earnings Headlines

LivaNova (LIVN) Stock Looks Undervalued As Its 60% Three Year Run Continues
October 9 at 7:26 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/livanova-livn-stock-looks-undervalued-211746846.html
LivaNova (LIVN) Narrative Keeps Fair Value In Focus As Shares Cool
October 9 at 7:26 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/livanova-livn-narrative-keeps-fair-181139771.html
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan.tc pixel
 |  Base Camp Trading (Ad)
LivaNova PLC (NASDAQ:LIVN) Stock Has Consensus Target Price of $87.75
October 9 at 2:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31101755
LivaNova (NASDAQ:LIVN) Raised to Strong-Buy at Barclays
October 8 at 6:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099307
LivaNova (NASDAQ:LIVN) Stock Breaks Below 50-Day Moving Average - Here's Why
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082135
See More LivaNova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LivaNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LivaNova and other key companies, straight to your email.

About LivaNova

LivaNova (NASDAQ:LIVN) (NASDAQ: LIVN) is a medical device company that develops and markets technologies for the treatment of cardiovascular and neurological conditions. The company’s principal businesses are organized around its Cardiopulmonary and Neuromodulation segments.

Its cardiopulmonary portfolio includes heart-lung machines, oxygenators, perfusion systems and other equipment used during cardiopulmonary bypass procedures, as well as technologies designed to support cardiac surgery and related clinical applications. In neuromodulation, LivaNova offers VNS Therapy, an implantable system that uses electrical stimulation of the vagus nerve as an adjunctive treatment for drug-resistant epilepsy and treatment-resistant depression in eligible patients.

LivaNova was created in 2015 through the merger of Cyberonics, a U.S. neuromodulation company, and Sorin, an Italian cardiovascular device business. The company serves hospitals, clinicians and patients in the United States and international markets, with products distributed across regions including Europe and other markets worldwide. Damien McDonald has served as LivaNova’s chief executive officer since 2018.

View LivaNova Profile
Earnings Tools